Bessemer Group
ADMA icon

Bessemer Group’s ADMA Biologics ADMA Stock Holding History

Bessemer Group’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49M Buy
177,713
+227
+0.1% +$2.07K ﹤0.01% 916
2026
Q1 		$1.6M Sell
177,486
-1,137
-0.6% -$17.9K ﹤0.01% 854
2025
Q4 		$3.26M Buy
178,623
+178,135
+36,503% +$3M 0.01% 605
2025
Q3 		$7K Sell
488
-72
-13% -$1.23K ﹤0.01% 2040
2025
Q2 		$10K Buy
560
+74
+15% +$1.51K ﹤0.01% 1803
2025
Q1 		$10K Sell
486
-75
-13% -$1.3K ﹤0.01% 1753
2024
Q4 		$10K Buy
561
+307
+121% +$5.78K ﹤0.01% 1745
2024
Q3 		$5K Buy
+254
New +$3.95K ﹤0.01% 1893

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bessemer Group's ADMA Position: Q2 2026 in Review

Bessemer Group increased its ADMA Biologics (ADMA) stake by 0.13% in Q2 2026, buying an estimated $2.07K and bringing the position to 177,713 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #916.

Bessemer Group first reported a position in ADMA in Q3 2024 and has held it in 8 quarters since. The position peaked at $3.26M in Q4 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Bessemer Group held 177,713 shares of ADMA Biologics worth $1.49M as of Q2 2026.
  • Bessemer Group bought 227 ADMA Biologics shares in Q2 2026, an estimated $2.07K.
  • ADMA Biologics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #916 holding.
  • Bessemer Group first reported a position in ADMA Biologics in Q3 2024 and has held it in 8 quarters since.
  • Bessemer Group's ADMA Biologics position peaked at $3.26M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.